U.S. markets open in 9 hours 27 minutes
  • S&P Futures

    4,440.75
    +2.75 (+0.06%)
     
  • Dow Futures

    34,667.00
    +23.00 (+0.07%)
     
  • Nasdaq Futures

    15,295.00
    -8.50 (-0.06%)
     
  • Russell 2000 Futures

    2,257.90
    +2.70 (+0.12%)
     
  • Crude Oil

    73.32
    +0.02 (+0.03%)
     
  • Gold

    1,752.20
    +2.40 (+0.14%)
     
  • Silver

    22.67
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1744
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4100
    +0.0740 (+5.54%)
     
  • Vix

    18.63
    -2.24 (-10.73%)
     
  • GBP/USD

    1.3725
    +0.0004 (+0.03%)
     
  • USD/JPY

    110.3990
    +0.0980 (+0.09%)
     
  • BTC-USD

    44,296.20
    +240.70 (+0.55%)
     
  • CMC Crypto 200

    1,106.81
    -2.11 (-0.19%)
     
  • FTSE 100

    7,078.35
    -5.02 (-0.07%)
     
  • Nikkei 225

    30,238.42
    +599.02 (+2.02%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NERV, KNDI and JFU

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / February 5, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Minerva Neurosciences, Inc. (NASDAQ:NERV)
Class Period: May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline: February 8, 2021

The complaint alleges that throughout the class period Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in NERV: http://www.kleinstocklaw.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?id=12719&from=1

Kandi Technologies Group, Inc. (NASDAQ:KNDI)
Class Period: March 15, 2019 - November 27, 2020
Lead Plaintiff Deadline: February 9, 2021

The KNDI lawsuit alleges Kandi Technologies Group, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Kandi artificially inflated its reported revenues through undisclosed related party transactions, or otherwise had relationships with key customers that indicated those customers did not have an arms length relationship with Kandi; (ii) the majority of Kandi's sales in the past year had been to undisclosed related parties and/or parties with such a close relationship and history with Kandi that it cast doubt on the arms-length nature of their relationship; (iii) all the foregoing, once revealed, was foreseeably likely to cast doubt on the validity of Kandi's reported revenues and, in turn, have a foreseeable negative impact on the Company's reputation and valuation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in KNDI: http://www.kleinstocklaw.com/pslra-1/kandi-technologies-group-inc-loss-submission-form?id=12719&from=1

9F Inc. (NASDAQ:JFU)
Lawsuit on behalf of investors who purchased JFU securities: (1) pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company's August 14, 2019 initial public offering; and/or (2) between August 14, 2019 and September 29, 2020.
Lead Plaintiff Deadline: March 22, 2021

The JFU lawsuit alleges that throughout the class period, 9F Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the purported value and benefits of the Company's financial institution partners and its tri-party cooperation business model did not in fact exist and/or were materially overstated, given that 9F and Property and Casualty Company Limited ("PICC") had been engaged in an ongoing contractual dispute regarding payment of service fees under their cooperation agreement; (2) the collectability of service fees owed to 9F by PICC under the cooperation agreement was in doubt and at serious risk of non-payment; (3) there was a significant risk that PICC would no longer provide credit insurance and guarantee protection to investors and institutional funding partners; (4) as a result of the foregoing, the Company's platform, business model, reputation and financial results had been materially impaired; and (5) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in JFU: http://www.kleinstocklaw.com/pslra-1/9f-inc-loss-submission-form?id=12719&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/628169/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-NERV-KNDI-and-JFU